孟鲁司特联合布地奈德治疗在改善支气管哮喘患儿免疫及肺功能中的作用  

Effects of Montelukast combined with budesonide on improving immunity and lung function in children with bronchial asthma

作　　者：赵明胜 张卫星[2] 常绍红 Zhao Ming-sheng;Zhang Wei-xing;Chang Shao-hong(Department of Pediatrics,Chengguan Township Health Center of Fengqiu,Xinxiang 453300,Henan,China;Department of Pediatrics,Xinxiang Central Hospital,Xinxiang 453000,Henan,China)

机构地区：[1]封丘县城关乡卫生院儿科,河南新乡453300 [2]新乡市中心医院儿科,河南新乡453000

出　　处：《四川生理科学杂志》2024年第11期2535-2537,共3页

摘　　要：目的:探讨孟鲁司特联合布地奈德治疗对支气管哮喘患儿免疫功能、肺功能的影响。方法:回顾性分析2022年1月至2023年6月期间本院收治的94例支气管哮喘患儿的临床资料,根据治疗方案的不同将患儿分为对照组(49例,采用布地奈德治疗200μg分为早晚两次雾化吸入)和观察组(采用孟鲁司特4-5 mg口服)联合布地奈德治疗,45例。治疗3 m后,采用酶联免疫吸附法检测特异性Ig E(Specific IgE,sIgE)及白介素-10(Interleukin-10,IL-10)水平,采用流式细胞仪检测CD4^(+)CD25^(+)Treg水平,采用肺功能仪测定肺功能指标,包括第一秒用力呼气量(Forced expiratory volume in first second,FEV1)、用力肺活量(Forced vital capacity,FVC)及第一秒用力呼气量占所有呼气量的比例(FEV1/FVC),比较两组临床疗效及不良反应。结果:观察组的治疗总有效率明显高于对照组(93.33%vs 77.55%,P<0.05)。治疗后,观察组的CD4^(+)CD25^(+)Treg水平显著高于对照组,sIgE、IL-10水平均显著低于对照组(P<0.05)。治疗后,观察组FEV1、FVC及FEV1/FVC均比对照组显著提高(P<0.05)。两组的不良反应总发生率无显著差异(P>0.05)。结论:布地奈德联合孟鲁司特治疗支气管哮喘患儿,能提高临床疗效,改善患儿CD4^(+)CD25^(+)Treg、sIgE、IL-10水平及肺功能,且安全性较高。Objective:To investigate the effects of Montelukast combined with budesonide on immune function and lung function in children with bronchial asthma.Methods:A retrospective analysis was conducted on the clinical data of 94 children with bronchial asthma admitted to our hospital from January 2022 to June 2023.The children were divided into a control group(49 cases,treated with budesonide 200μg divided into morning and evening nebulization inhalation)and an observation group(45 cases,treated with montelukast 4-5 mg orally combined with budesonide)according to different treatment plans.After 3 months of treatment,the levels of specific IgE(sIgE)and interleukin-10(IL-10)were detected by enzyme-linked immunosorbent assay,the level of CD4^(+)CD25^(+)Treg was detected by flow cytometry,and the lung function indicators(forced expiratory volume in the first second(FEV1),forced vital capacity(FVC),and the ratio of forced expiratory volume in first second to total expiratory volume(FEV1/FVC))were measured by a pulmonary function tester.The clinical efficacy and adverse reactions of the two groups were compared.Results:The total effective rate of the observation group was 93.33%,which was significantly higher than that of the control group(77.55%,P<0.05).After treatment,CD4^(+)CD25^(+)Treg levels in the observation group were significantly higher than in the control group,and sIgE and IL-10 levels were significantly lower than in the control group(P<0.05).After treatment,FEV1,FVC,and FEV1/FVC in the observation group were significantly higher than in the control group(P<0.05).The two groups had no significant difference in the total incidence of adverse reactions(P>0.05).Conclusion:Budesonide combined with Montelukast in children with bronchial asthma can improve clinical efficacy,CD4^(+)CD25^(+)Treg,sIgE,IL-10 levels,and lung function,and has high safety.

关 键 词：孟鲁司特 布地奈德 支气管哮喘 CD4^(+)CD25^(+)Treg SIGE 

分 类 号：R725.6[医药卫生—儿科]